A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial

Hodgson, 2005, The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050, Br J Cancer, 92, 587, 10.1038/sj.bjc.6602307

Leigh, 2002, Malignant mesothelioma in Australia, 1945–2000, Am J Ind Med, 41, 188, 10.1002/ajim.10047

Andreopoulou, 2004, The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma, Ann Oncol, 15, 1406, 10.1093/annonc/mdh356

Steele, 2000, Phase II study of vinorelbine in patients with malignant pleural mesothelioma, J Clin Oncol, 18, 3912, 10.1200/JCO.2000.18.23.3912

Byrne, 1999, Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study, J Clin Oncol, 17, 25, 10.1200/JCO.1999.17.1.25

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Van Meerbeeck, 2004, A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM) an intergroup study of the EORTC Lung Cancer Group and NCIC, J Clin Oncol, 22, 622s

Muers, 2004, BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112, Thorax, 59, 144, 10.1136/thorax.2003.009290

Edwards, 2000, Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems, Thorax, 55, 731, 10.1136/thorax.55.9.731

Herndon, 1998, Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B, Chest, 113, 723, 10.1378/chest.113.3.723

Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145

Yates, 1997, Malignant mesothelioma in south east England: clinicopathological experience of 272 cases, Thorax, 52, 507, 10.1136/thx.52.6.507

O'Brien, 2004, Malignant mesothelioma—the UK experience, Lung Cancer, 45, S133, 10.1016/j.lungcan.2004.04.024

Smith, 2001, Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol, 19, 1336, 10.1200/JCO.2001.19.5.1336

Middleton, 1998, Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma, Ann Oncol, 9, 269, 10.1023/A:1008236010868

Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452

Palmer, 1994, Chemotherapy prolongs survival in inoperable pancreatic carcinoma, Br J Surg, 81, 882, 10.1002/bjs.1800810629

Scheithauer, 1993, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer, BMJ, 306, 752, 10.1136/bmj.306.6880.752

Pyrhonen, 1995, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer, Br J Cancer, 71, 587, 10.1038/bjc.1995.114